The estimated Net Worth of Partners L P/Ilbiotechnolog... is at least $52.9 Milion dollars as of 24 March 2014. Partners Ilbiotechnolog owns over 78,226 units of Palatin Technologies stock worth over $186,150 and over the last 15 years Partners sold PTN stock worth over $52,724,136.
Partners has made over 20 trades of the Palatin Technologies stock since 2009, according to the Form 4 filled with the SEC. Most recently Partners sold 78,226 units of PTN stock worth $5,482,860 on 24 March 2014.
The largest trade Partners's ever made was selling 3,753,000 units of Palatin Technologies stock on 31 March 2010 worth over $22,930,830. On average, Partners trades about 492,665 units every 75 days since 2009. As of 24 March 2014 Partners still owns at least 130,175 units of Palatin Technologies stock.
You can see the complete history of Partners Ilbiotechnolog stock trades at the bottom of the page.
Over the last 22 years, insiders at Palatin Technologies have traded over $3,929,269 worth of Palatin Technologies stock and bought 390,692 units worth $374,235 . The most active insiders traders include Austin W & Greenhouse David..., Partners L P/Ilbiotechnolog... a Carl Spana. On average, Palatin Technologies executives and independent directors trade stock every 76 days with the average trade being worth of $128,497. The most recent stock trade was executed by Stephen T Wills on 1 August 2024, trading 4,999 units of PTN stock currently worth $8,298.
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
Palatin Technologies executives and other stock owners filed with the SEC include: